Description

NATCO Pharma Limited, an Indian pharmaceutical enterprise established in 1981 and headquartered in Hyderabad, is dedicated to the development, manufacturing, and commercialization of diverse pharmaceutical products. Its core business encompasses the creation and production of both finished drug formulations and active pharmaceutical ingredients (APIs). The company's finished products address a wide spectrum of therapeutic needs, particularly in oncology, targeting cancers such as those affecting the blood, liver, kidneys, lungs, brain, breasts, and ovaries. Meanwhile, its API portfolio spans critical areas including cancer treatment, central nervous system disorders, pain alleviation, and cardiovascular health. Beyond this, NATCO Pharma provides specialized offerings like orthopedic treatments, which include both oral and injectable bisphosphonate medications, and innovative gastroenterology drugs designed for chronic hepatitis B and C. Furthermore, its product line extends to cardiology and diabetology, supplying solutions for conditions such as hypertension, stable angina, and congestive heart failure (CHF). The firm also engages in contract manufacturing services for other pharmaceutical entities. Globally, NATCO Pharma markets its diverse range of products across approximately 40 nations, with key markets including its home country, India, and the United States.